Comparing the current results to its competitors, Icad Inc reported Revenue decrease in the 1 quarter 2025 year on year by -1.61 %, slower than the combined decrease of the ICAD's competitors by -24.02 %, recorded in the same quarter.
Icad Inc's Comment on Competition and Industry Peers
iCAD operates in a highly competitive and rapidly evolving market with detection, density, and risk-related products offered by nationally and internationally recognized companies. Many competitors possess significantly greater financial, technical, and human resources and are well-established in the healthcare sector. These competitors may develop technologies or products that could render iCAD's offerings obsolete or noncompetitive and may obtain patent protection, regulatory approval, or product commercialization before iCAD, potentially limiting the company's competitive position. iCAD identifies efficacy, safety profile, feature differentiation, cost, and reimbursement as the primary factors influencing the success of its products.
despite revenue deterioration, Icad Inc increased its market share in this segment. company increased its market share in this segment to approximately 0.03 %.
July 29, 2024
In a significant development in the field of medical imaging, iCAD, a company specializing in artificial intelligence (AI) solutions, has announced a strategic commercial agreement with Windsong Radiology. This partnership marks the deployment of the ProFound AI Breast Health Suite, aimed at enhancing mammography capabilities through advanced AI-powered algorithms. Windsong Radiology is set to lead this initiative, becoming an early adopter of iCAD s innovative technology that promises to improve the accuracy and efficiency of breast cancer detection. The ProFound AI suite is designed to assist radiologists by streamlining the interpretation of mammograms, thereby potentially increasing early detection rates...
April 9, 2024
In an industry-first collaboration, American clinical radiology and AI-powered cancer detection company, iCAD, Inc., has joined forces with Canadian medical technology company, Densitas, Inc., global leaders in operational AI-driven breast cancer screening systems. The groundbreaking partnership, announced on April 9, 2024, is set to elevate the resonance of precision health care in the realm of women s health. With parallel expertise in AI imaging technology, the strategic partnership between these two industry leaders aims to provide end-to-end breast health care, creating an all-encompassing journey to address all aspects of women s breast health. This progressive endeavor is not just capable of exceeding...
April 2, 2024
Amidst the escalating complexities of cancer detection in the healthcare domain, innovation-driven medical technology company iCAD has unleashed its latest game-changer: ProFound Cloud. With a practicable vision of redefining the accessibility of critical insights for early detection of breast cancer, this revolutionary advancement is a testament to iCAD s recognition of the significance of integrating state-of-the-art technology with health solutions.Crafted as a medical marvel that stands at the intersection of technology and healthcare, ProFound Cloud intelligently inaugurates a novel perspective towards breast cancer detection, one that is driven by the efficiency, scalability, and accuracy of artificial...
American Oncology Network Inc is a healthcare services company that operates as a physician-led organization, providing comprehensive, community-based oncology care across the United States. They partner with oncologists, hospitals, and practices to deliver high-quality, value-based cancer care while focusing on patient-centric solutions.
Accuray Incorporated is a medical technology company that focuses on the development and sale of radiation therapy systems. Their business model revolves around providing advanced and precise treatment options to cancer patients by combining robotics and imaging technologies. By delivering innovative solutions, Accuray aims to improve patient outcomes and establish partnerships with healthcare providers worldwide.
Edap Tms Sa's business model revolves around providing minimally invasive medical devices and solutions for the treatment of urological diseases, specifically focusing on advanced ultrasound technologies for the diagnosis and treatment of prostate cancer and kidney stones.
Fonar Corporation operates as a medical technology company that specializes in the development, production, and marketing of magnetic resonance imaging (MRI) scanners. Their business model revolves around selling and servicing their proprietary MRI machines to healthcare facilities worldwide. They generate revenue through the sales of these scanners, as well as by providing additional services such as maintenance and support to their customers.
General Electric Companys business model centers on industrial operations, creating and delivering advanced technologies, products, and services across sectors such as power generation, aviation, healthcare, and renewable energy. The company emphasizes innovation and sustainability, aiming to enhance performance and efficiency for customers while tackling pressing societal and environmental issues.
Sources:
Icad Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Icad Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
